Effects of dexamethasone on CTLA-4 expression and apoptosis in lymphocytes obtained from children with mesangial proliferative nephritis

Chinese Journal of Contemporary Pediatrics

Volumn 11, Issue 12, 2009, Pages 957-960

  Wang, Feng Ying ^a   Lu, Si Guang ^a   Luo, Rong Hua ^a  

^a Tai'an Central Hospital   (China)

Author keywords

Apoptosis; Child; CTLA 4; Dexamethasone; Mesangial proliferative glomerulonephritis

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DEXAMETHASONE; FLUORESCEIN ISOTHIOCYANATE; PROPIDIUM IODIDE;

APOPTOSIS; ARTICLE; BLOOD SAMPLING; CELL CULTURE; CHILD; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; LYMPHOCYTE; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEIN EXPRESSION;

ANTIGENS, CD; APOPTOSIS; CHILD; DEXAMETHASONE; FEMALE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; LYMPHOCYTES; MALE;

EID: 75149124351     PISSN: 10088830     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. + T cells toward the Th1 subset by CTLA-4 costimulation[J]. J Immunol, 2000, 164(7):3554-3562.
2. Frauwirth KA, Thompson CB. Activation and inhibition of lymphocytes by costimulation[J]. J Clin Invest, 2002, 109(3):295-299.
3. Parrv RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobavashi SV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms[J]. Mol Cell Biol, 2005, 25(21):9543-9553.
4. Henson SM, Macaulav R, Kiani-Alikhan S, Akbar AN. The use of the inhibiotory receptors for modulating the immune responses[J]. Curr Pharm Des, 2008, 14(26):2643-2650.
5. Chinese source
6. Xia M, Casser J, Feige U. Dexamethasone enhances CTLA-4 expression during T cell activation[J]. Cell Mol Life Sci, 1999, 55(12):1649-1656.
7. Koper JW, Stolk RP, Delange P, Huizenga NA, Molijn GJ, Pols HA, et al. Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance[J]. Hum Genet, 1997, 99(5):663-668.
8. Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, Mittler RS. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement[J]. Immunity, 1996, 4(6):535-543.
9. Egen JG, Kuhns MS, Allison JP. CTLA4: new insights into its biological function and use in tumor immunotherapy[J]. Nat Immunol, 2002, 3(7):611-618.
10. Martin M, Schneider H, Azouz A, Rudd CE. Cytotoxic T lymphocyte antigen 4 and CD28 modulate cell surface raft expression in their regulation of T cell function[J]. J Exp Med, 2001, 194(11):1675-1681.
11. Kubsch S, Graulich E, Knop J, Steinbrink K. Suppressor activity of anergic T cells induced by IL-10-treated human dendritic cells: association with IL-2- and CTLA-4-dependent G1 arrest of the cell cycle regulated by p27Kip1[J]. Eur J Immunol, 2003, 33(7):1988-1997.
12. Contardi E, Palmisano GL, Tazzari PL, Martelli AM, Fala F, Fabbi M, et al. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction[J]. Int J Cancer, 2005, 117(4):538-550.
13. Laurent S, Palmisano GL, Martelli AM, Kato T, Tazzari PL, Pierri I, et al. CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis[J]. Br J Haematol, 2007, 136(4):597-608.
14. Harlin H, Hwang KW, Palucki DA, Kim O, Thompson CB, Boothbv M, et al. CTLA-4 engagement regulates NF-kappaB activation in vivo[J]. Eur J Immunol, 2002, 32(8):2095-2104.
15. Bour-Jordan H, Grogan JL, Tang Q, Auqer JA, Lockslev RM, Bluestone JA. CTLA-4 regulates the requirement for cytokine-induced signals in T(H)2 lineage commitment[J]. Nat Immunol, 2003, 4(2):182-188.